Johnson & Johnson / Vertex Pharmaceuticals (telaprevir ex-NA/ex-Far East rights)

Chronic Hepatitis C Virus (HCV) Infection

Disease Overview

Hepatitis C virus is a bloodborne pathogen that causes chronic liver inflammation, leading to cirrhosis, liver failure, and hepatocellular carcinoma in a significant fraction of infected patients. At the time of the 2006 deal, standard-of-care was 48 weeks of pegylated interferon plus ribavirin, which cured fewer than half of genotype 1 patients and carried significant tolerability burden. Genotype 1 dominates US epidemiology and was the hardest to cure.

Competitive Landscape

In June 2006, the HCV treatment landscape was defined by two pegylated interferons — Roche/Genentech's Pegasys and Schering-Plough's PEG-Intron — combined with ribavirin (Copegus, Rebetol). Genotype 1 sustained virological response (SVR) rates topped out around 40-50% with significant flu-like and psychiatric tolerability issues. The race to develop the first direct-acting antiviral (DAA) protease inhibitor was on, with Vertex's VX-950 (telaprevir) and Schering-Plough's boceprevir as the two leading NS3/4A inhibitor candidates. Vertex chose Janssen/Tibotec — already a leader in HIV antivirals — as ex-NA/ex-Far East partner for $165M upfront plus up to $380M milestones and mid-20s royalties. Mitsubishi Tanabe held Far East rights. The deal validated DAA-class economics and helped fund pivotal PROVE/ADVANCE/ILLUMINATE trials. Telaprevir launched as Incivek/Incivo in 2011 with breakthrough SVR rates of 69-75% in genotype 1 treatment-naive patients, achieving the fastest pharma launch in history. The franchise was rapidly displaced by Gilead's Sovaldi (sofosbuvir, 2013) and Harvoni (2014) interferon-free regimens; Vertex discontinued Incivek in August 2014. The deal nonetheless funded Vertex's pivot to cystic fibrosis that became its enduring franchise.